EUVIMEDEUVIMED entdecken
Crossref

Predictive Model of Objective Response to Nivolumab Monotherapy for Advanced Renal Cell Carcinoma by Machine Learning Using Genetic and Clinical Data: The SNiP-RCC Study

Masaki Shiota iD, Shota Nemoto, Ryo Ikegami, Tokiyoshi Tanegashima, Leandro Blas iD, Hideaki Miyake, Masayuki Takahashi, Mototsugu Oya, Norihiko Tsuchiya iD, Naoya Masumori, Keita Kobayashi iD, Wataru Obara iD und 16 weitere

JCO Clinical Cancer Informatics · 2025-04 · (9)

DOI: 10.1200/cci-24-00167 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Clinical Cancer Informatics, 2025-04. Verfasst von Masaki Shiota und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. Hauptthemen laut MEDLINE: Nivolumab, Carcinoma, Renal Cell, Machine Learning, Kidney Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Anti–PD-1 antibodies are widely used for cancer treatment, including in advanced renal cell carcinoma (RCC). However, the therapeutic response varies among patients. This study aimed to predict tumor response to nivolumab anti–PD-1 antibody treatment for advanced RCC by integrating genetic and clinical data using machine learning (ML). METHODS Clinical and single-nucleotide polymorphism (SNP) data obtained in the SNPs in nivolumab PD-1 inhibitor for RCC study, which enrolled Japanese patients treated with nivolumab monotherapy for advanced clear cell RCC, were used. A point-wise linear (PWL) algorithm, logistic regression with elastic-net regularization, and eXtreme Gradient Boosting were used in this study. AUC values for objective response and C-indices for progression-free survival (PFS) were calculated to evaluate the utility of the models. RESULTS Among the three ML algorithms, the AUC values to predict objective response were highest for the PWL algorithm among all the data sets. Three predictive models (clinical model, small SNP model, and large SNP model) were created by the PWL algorithm using the clinical data alone and using eight and 49 SNPs in addition to the clinical data. C-indices for PFS by the clinical model, small SNP model, and large SNP model were 0.522, 0.600, and 0.635, respectively. CONCLUSION The results demonstrated that the SNP models created by ML produced excellent predictions of tumor response to nivolumab monotherapy for advanced clear cell RCC and will be helpful in treatment decisions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NivolumabCarcinoma, Renal CellMachine LearningKidney NeoplasmsAntineoplastic Agents, ImmunologicalHumansPolymorphism, Single NucleotideMaleFemaleMiddle AgedAgedAlgorithmsPrognosisTreatment OutcomeBiomarkers, TumorImmune Checkpoint Inhibitors

Substanzen

NivolumabAntineoplastic Agents, ImmunologicalBiomarkers, TumorImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Industrial & Digital Business Unit, Hitachi, Ltd, Tokyo, Japan.
  • Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan.
  • Department of Urology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.
  • Department of Urology, Keio University School of Medicine, Tokyo, Japan.
  • Department of Urology, Faculty of Medicine, Yamagata University, Yamagata, Japan.

ORCID-Profile: Masaki Shiota, Leandro Blas, Norihiko Tsuchiya, Keita Kobayashi, Wataru Obara, Masahiro Nozawa, Kojiro Ohba, Shusuke Akamatsu, Takanobu Motoshima, Shuichi Tatarano

Zitieren

APA

Shiota, M., Nemoto, S., Ikegami, R., Tanegashima, T., Blas, L., Miyake, H., Takahashi, M., Oya, M., Tsuchiya, N., Masumori, N., Kobayashi, K., Obara, W., Shinohara, N., Fujimoto, K., Nozawa, M., Ohba, K., Ohyama, C., Hashine, K., Akamatsu, S., …, & Eto, M. (2025). Predictive Model of Objective Response to Nivolumab Monotherapy for Advanced Renal Cell Carcinoma by Machine Learning Using Genetic and Clinical Data: The SNiP-RCC Study. JCO Clinical Cancer Informatics. https://doi.org/10.1200/cci-24-00167

Vancouver

Shiota M, Nemoto S, Ikegami R, Tanegashima T, Blas L, Miyake H, et al. Predictive Model of Objective Response to Nivolumab Monotherapy for Advanced Renal Cell Carcinoma by Machine Learning Using Genetic and Clinical Data: The SNiP-RCC Study. JCO Clinical Cancer Informatics. 2025. doi:10.1200/cci-24-00167

BibTeX
@article{Shiota2025,
  author = {Shiota, Masaki and Nemoto, Shota and Ikegami, Ryo and Tanegashima, Tokiyoshi and Blas, Leandro and Miyake, Hideaki and Takahashi, Masayuki and Oya, Mototsugu and Tsuchiya, Norihiko and Masumori, Naoya and Kobayashi, Keita and Obara, Wataru and Shinohara, Nobuo and Fujimoto, Kiyohide and Nozawa, Masahiro and Ohba, Kojiro and Ohyama, Chikara and Hashine, Katsuyoshi and Akamatsu, Shusuke and Motoshima, Takanobu and Mita, Koji and Gotoh, Momokazu and Tatarano, Shuichi and Fujisawa, Masato and Tomita, Yoshihiko and Mukai, Shoichiro and Ito, Keiichi and Eto, Masatoshi},
  title = {Predictive Model of Objective Response to Nivolumab Monotherapy for Advanced Renal Cell Carcinoma by Machine Learning Using Genetic and Clinical Data: The SNiP-RCC Study},
  journal = {JCO Clinical Cancer Informatics},
  year = {2025},
  number = {9},
  doi = {10.1200/cci-24-00167}
}
Kostenlos starten →